Bold Vision.
Innovation at its best.

For almost 30 years, ProPhase has been relentlessly focused on enhancing wellness and improving health. Historically, we have been a diversified medical science and technology company that delivers breakthrough, clinically shown supplements, and OTC manufacturing. We are now rapidly developing into a true diagnostics, genomics and biotech company. We are diversifying our ProPhase Diagnostics state-of-the-art CLIA laboratories for COVID-19 Testing with traditional clinical lab testing, whole genome sequencing, and diagnostic cancer tests. We are also in the early stages of developing potentially groundbreaking cancer therapeutics.

In 2020, we pivoted to build out state-of-the-art CLIA labs for COVID-19 diagnostic testing. In 2021, we acquired Nebula Genomics to provide Whole Genome Sequencing to the broad public in addition to research institutions. In mid-2022, we formed ProPhase BioPharma to license, develop and commercialize drugs and compounds with enormous potential. Our first licensing efforts included Equivir (OTC) and Equivir G (Rx), broad-based anti-viral compounds. Equivir OTC could be commercialized as early as the second half of 2023. We then licensed Linebacker 1 and 2, compounds that have multi-billion-dollar potential as cancer co-therapies. In late 2022, we acquired the BE-Smart Esophageal Diagnostic Cancer test that has multi-billion-dollar potential and could be commercialized as early as 2024.